Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease

Food and Chemical Toxicology

Volumn 63, Issue , 2014, Pages 166-173

  Li, Lake ^a   Hai, Jie ^a   Li, Zhiqiang ^a   Zhang, Yongli ^a   Peng, Hua ^a   Li, Kun ^a   Weng, Xiaogang ^a  

^a The Third Hospital of Xinxiang Medical University   (China)

Author keywords

Autophagy; NAFLD; NF B; Resveratrol

Indexed keywords

ADIPONECTIN; GLUTATHIONE PEROXIDASE; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; RESVERATROL; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; GLUCOSE TOLERANCE; HETEROZYGOTE; HISTOPATHOLOGY; INFLAMMATION; INSULIN RESISTANCE; KNOCKOUT MOUSE; LIPID DIET; LIPID PEROXIDATION; LIVER FIBROSIS; LIVER INJURY; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TREATMENT DURATION; WILD TYPE;

MURINAE; MUS;

ALANINE AMINOTRANSFERASE; ALT; AMP-ACTIVATED PROTEIN KINASE; AMPK; ASPARTATE AMINOTRANSFERASE; AST; AUTOPHAGY; GLUCOSE TOLERANCE TEST; GLUTATHIONE PEROXIDASE; GPX; GTT; HCC; HEPATOCELLULAR CARCINOMA; IL; INHIBITOR OF KAPPAB ALPHA; INSULIN TOLERANCE TEST; INTERLEUKIN; ITT; IΚBΑ; MALONDIALDEHYDE; MDA; NAFLD; NASH; NF-ΚB; NON-ALCOHOLIC FATTY LIVER DISEASE; NON-ALCOHOLIC STEATOHEPATITIS; NUCLEAR FACTOR-KAPPAB; PBS; PHOSPHATE BUFFERED SOLUTION; RESVERATROL; SREBP-1C; STEROL REGULATORY ELEMENT-BINDING PROTEIN-1C; TNF; TUMOR NECROSIS FACTOR; ULK1; UNC-51-LIKE KINASE 1;

ANIMALS; AUTOPHAGY; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DNA PRIMERS; FATTY LIVER; INFLAMMATION; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; STILBENES;

EID: 84888800151     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2013.08.036     Document Type: Article

References (30)

1. Adachi M., Osawa Y., Uchinami H., Kitamura T., Accili D., Brenner D.A. The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells. Gastroenterology 2007, 132:1434-1446.
2. Amir M., Czaja M.J. Autophagy in nonalcoholic steatohepatitis. Expert Review of Gastroenterology and Hepatology 2011, 5:159-166.
3. Aoun M., Michel F., Fouret G., Casas F., Jullien M., Wrutniak-Cabello C., Ramos J., Cristol J.P., Coudray C., Carbonneau M.A., Feillet-Coudray C. A polyphenol extract modifies quantity but not quality of liver fatty acid content in high-fat-high-sucrose diet-fed rats: possible implication of the sirtuin pathway. British Journal of Nutrition 2010, 104:1760-1770.
4. Bishayee A., Barnes K.F., Bhatia D., Darvesh A.S., Carroll R.T. Resveratrol suppresses oxidative stress and inflammatory response in diethylnitrosamine-initiated rat hepatocarcinogenesis. Cancer Prevention Research 2010, 3:753-763.
5. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., Grundy S.M., Hobbs H.H. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
6. Brunt E.M., Kleiner D.E., Wilson L.A., Belt P., Neuschwander-Tetri B.A. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011, 53:810-820. NASH Clinical Research Network (CRN).
7. Bujanda L., Hijona E., Larzabal M., Beraza M., Aldazabal P., García-Urkia N., Sarasqueta C., Cosme A., Irastorza B., González A., Arenas J.I. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterology 2008, 8:40.
8. Bustin S.A., Benes V., Garson J.A., Hellemans J., Huggett J., Kubista M., Mueller R., Nolan T., Pfaffl M.W., Shipley G.L., Vandesompele J., Wittwer C.T. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clinical Chemistry 2009, 55:611-622.
9. Cheng K.K., Iglesias M.A., Lam K.S., Wang Y., Sweeney G., Zhu W., Vanhoutte P.M., Kraegen E.W., Xu A. APPL1 potentiates insulin-mediated inhibition of hepatic glucose production and alleviates diabetes via Akt activation in mice. Cell Metabolism 2009, 9:417-427.
10. Cheng Y., Qiu F., Ye Y.C., Guo Z.M., Tashiro S., Onodera S., Ikejima T. Autophagy inhibits reactive oxygen species-mediated apoptosis via activating p38-nuclear factor-kappa B survival pathways in oridonin-treated murine fibrosarcoma L929 cells. FEBS Journal 2009, 276:1291-1306.
11. Colak Y., Ozturk O., Senates E., Tuncer I., Yorulmaz E., Adali G., Doganay L., Enc F.Y. SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Medical Science Monitor 2011, 17:HY59.
12. Gómez-Zorita S., Fernández-Quintela A., Macarulla M.T., Aguirre L., Hijona E., Bujanda L., Milagro F., Martínez J.A., Portillo M.P. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. British Journal of Nutrition 2012, 107:202-210.
13. Jeandet P., Delaunois B., Aziz A., Donnez D., Vasserot Y., Cordelier S., Courot E. Metabolic engineering of yeast and plants for the production of the biologically active hydroxystilbene, resveratrol. Journal of Biomedicine and Biotechnology 2012, 2012:579089.
14. Liu H.Y., Han J., Cao S.Y., Hong T., Zhuo D., Shi J., Liu Z., Cao W. Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: inhibition of FoxO1-dependent expression of key autophagy genes by insulin. Journal of Biological Chemistry 2009, 284:31484-31492.
15. Mizushima N. The role of the Atg1/ULK1 complex in autophagy regulation. Current Opinion in Cell Biology 2010, 22:132-139.
16. Niaz A., Ali Z., Nayyar S., Fatima N. Prevalence of NAFLD in healthy and young male individuals. ISRN Gastroenterology 2011, 2011:363546.
17. Park H.J., Lee J.Y., Chung M.Y., Park Y.K., Bower A.M., Koo S.I., Giardina C., Bruno R.S. Green tea extract suppresses NFκB activation and inflammatory responses in diet-induced obese rats with nonalcoholic steatohepatitis. Journal of Nutrition 2012, 142:57-63.
18. Patel K.R., Scott E., Brown V.A., Gescher A.J., Steward W.P., Brown K. Clinical trials of resveratrol. Annals of the New York Academy of Sciences 2011, 1215:161-169.
19. Pattingre S., Tassa A., Qu X., Garuti R., Liang X.H., Mizushima N., Packer M., Schneider M.D., Levine B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005, 122:927-939.
20. Polyzos S.A., Kountouras J., Zavos C., Deretzi G. Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease. Journal of Clinical Gastroenterology 2012, 46:272-284.
21. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB Journal 2008, 22:659-661.
22. Rector R.S., Thyfault J.P., Wei Y., Ibdah J.A. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World Journal of Gastroenterology 2008, 14:185-192.
23. Shang J., Chen L.L., Xiao F.X., Sun H., Ding H.C., Xiao H. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacologica Sinica 2008, 29:698-706.
24. Singh R., Kaushik S., Wang Y., Xiang Y., Novak I., Komatsu M., Tanaka K., Cuervo A.M., Czaja M.J. Autophagy regulates lipid metabolism. Nature 2009, 458:1131-1135.
25. Starley B.Q., Calcagno C.J., Harrison S.A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010, 51:1820-1832.
26. Szkudelski T. The insulin-suppressive effect of resveratrol - an in vitro and in vivo phenomenon. Life Sciences 2008, 82:430-435.
27. Wu D., Wang X., Zhou R., Yang L., Cederbaum A.I. Alcohol steatosis and cytotoxicity: the role of cytochrome P4502E1 and autophagy. Free Radical Biology and Medicine 2012, 53:1346-1357.
28. Xiao J., Ching Y.P., Liong E.C., Nanji A.A., Fung M.L., Tipoe G.L. Garlic-derived S-allylmercaptocysteine is a hepato-protective agent in non-alcoholic fatty liver disease in vivo animal model. European Journal of Nutrition 2013, 52:179-191.
29. Xin P., Han H., Gao D., Cui W., Yang X., Ying C., Sun X., Hao L. Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats. Food and Chemical Toxicology 2012, 52C:12-18.
30. Yousefi S., Perozzo R., Schmid I., Ziemiecki A., Schaffner T., Scapozza L., Brunner T., Simon H.U. Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nature Cell Biology 2006, 8:1124-1132.